Vivus has had a tough time launching obesity drug Qysmia, and shares have taken a beating, losing nearly half of their value over the past year. This has caused some activist investors, led by hedge fund First Manhattan, to call for a change in leadership, including looking to replace the drugmaker's CEO and nine directors.
In this video, health-care analyst David Williamson discusses Vivus' surprise decision to push back the shareholder meeting from Monday to Thursday, First Manhattan's aggressive response, and what the outcome could mean for investors in Vivus and its obesity-drug rival.
